Penn Researchers Use The Abdomen To Deliver Oxygen To Assist Ailing Lungs

"This is an alternate, novel way to deliver oxygen to the body that does not attempt to wring more function out of an already injured lung, by using ventilator settings that can actually exacerbate the underlying lung injury. The only other alternates that can 'rest' the lung involve variations of bypass machine technology, all of which require anticoagulation," explains Joseph Friedberg, MD, Associate Professor of Surgery and principal investigator of this study. "The ability to rest the lungs and provide supplemental oxygen with a technique that appears nontoxic and does not require anticoagulants could have huge implications some day for patients suffering from potentially reversible pulmonary failure from such diseases as: anthrax, bird flu, SARS, trauma, ARDS, pulmonary embolism, pneumonia and others. Sometimes patients have a condition in which they might have a chance to recover if they could survive the most severe phase of their disease."

The system these researchers developed involves recirculating a gas-carrying liquid through the abdomen to deliver oxygen. They tested the system in adult pigs that were put to sleep and ventilated with low concentrations of oxygen to simulate lung failure. Using this technique, they observed an increase in arterial oxygen saturation (the actual percentage of blood that's carrying oxygen) from 73% to 89%. Doctors generally aim to keep the oxygen saturation of patients in the 90% range. Friedberg adds, "If this experimental finding can be translated to a critical care setting, this could be a potentially life-saving increase in oxygenation."

Friedberg's idea was inspired by a similar technique, already used for patients suffering from kidney failure -- peritoneal dialysis -- in which a catheter is placed into the abdominal cavity and the blood is cleansed by using the lining of the abdominal cavity to exchange toxins and electrolytes. Friedberg wondered if it would be possible to use the lining of the abdominal cavity for gas exchange, like a "supplemental" lung, analogous to the way it is used like a "supplemental" kidney with peritoneal dialysis. To test this idea, it was clear that a nontoxic liquid capable of dissolving large volumes of gas would be needed. Friedberg felt perfluorocarbons were well suited for this purpose.

"These were short-term proof of principle experiments performed on otherwise healthy pigs. What we found, however, was that the circuit was able to increase arterial oxygen levels by a significant degree and that the technique was simple and safe to perform in these short-term studies. We have shown that this technique has potential. The next steps would be to optimize the effect, by testing it in a lung disease model and assess long-term safety," states Friedberg.

Friedberg addresses the potential for this technology in treating critically ill patients, "I have seen patients die who might have survived if there had been some way to buy them more time for their lungs to recover. They just exceeded the ability of the ventilator to exchange enough gas through their sick lungs. Also, there is a phenomenon of ventilator-induced lung injury, a vicious cycle where the high vent settings required to support someone with lung failure actually exacerbate the underlying lung disease, requiring even more vent support. A technique like abdominal perfusion, if proven to be safe and effective, could be used to short-circuit this positive feedback loop and 'rest' the lungs, rather than enter that potentially fatal spiral."

The results of this study are in Chest (http://www.chestjournal.org/), the journal of the American College of Chest Physicians. The article is titled "Peritoneal Perfusion with Oxygenated Perfluorocarbon Augments Systemic Oxygenation." Co-authors are Shamus Carr and Joshua Collins of Penn, as well as Joshua Cantor, Atul Rao, and Thiru Lakshman of Thomas Jefferson University, Philadelphia.

This study was funded by the Department of Surgery at Thomas Jefferson University Hospital. The former Neuron Therapeutics, Inc. donated the perfluorocarbon for use in this study.